Objective: To examine the association between smoking and changes in cognitive function over time in elderly persons without dementia. Methods: The results of neuropsychological tests grouped into domains of memory, abstractvisuospatial, and language, from several intervals over a 5-year period in 791 elderly patients without dementia or cognitive impairment. Smoking history was categorized as never, current, or past smokers and related to the slope of performance in each cognitive domain using generalized estimating equations. Results: Performance in all cognitive domains declined over time. Memory performance declined more rapidly among current smokers aged Ͼ75 years than in nonsmokers similar in age, including those who never smoked or had quit smoking. The effect was stronger among those without an APOE-ε4 allele. There was no association between smoking and performance in any cognitive domain in persons aged Ͻ75 years, and there was no association between past smoking and performance on any of the three cognitive factors at any time interval in either age group. Conclusion: Current smokers aged Ͼ75 years perform more poorly on cognitive tests and appear to decline in memory more rapidly than their peers who do not smoke, especially if they lack the APOE-ε4 allele. Smoking does not affect cognitive performance in those persons aged Ͻ75 years. NEUROLOGY 2005;65:870-875 Methods. Participants were part of a longitudinal study of Medicare recipients aged 65 years or older residing in northern Manhattan (Washington Heights, Hamilton Heights, Inwood). 17 Each participant underwent an in-person interview of general health and function at the time of study entry followed by a standard assessment including medical history, physical and neurologic examination, as well as a neuropsychological battery. 18 Baseline data were collected from 1992 through 1994. Follow-up data were collected during evaluations at sequential intervals of approximately 18 months, performed from 1994 to 1996, 1996 to 1997, and 1997 to 1999. In this elderly population, some participants did not complete follow-up at all intervals due to refusal to participate further, relocation, or death. About one-half of participants were evaluated at the third follow-up visit. This study was approved by the institutional review board of the Columbia-Presbyterian Medical Center.
About 1% of people aged 65 to 69 years have dementia, and this proportion increases with age to approximately 60% for people over age 95. 1 There are inconclusive data relating smoking, a modifiable risk factor associated with many age-related diseases such as atherosclerosis or cerebrovascular disease, 2, 3 to cognitive decline and dementia. [4] [5] [6] Although casecontrol studies suggest that smoking lowers the risk of Alzheimer disease (AD), 6 prospective studies have shown an increased risk 4, 5, 7 or no association with AD. [8] [9] [10] The effects of nicotine-induced increases in nicotinic acetylcholine receptors (nAChR) and protection against age-related nAChR decline are inconsistent because studies have also shown a reduction in nAChR in AD. 11 Whether or not smoking affects cognitive function in elderly without dementia or cognitive impairment remains unclear. Most of the evidence derives from retrospective or cross-sectional studies using only a single time point for the analysis. 12, 13 Longitudinal studies have provided only global neuropsychological assessments, did not have the ability to detect early stages of cognitive decline, [14] [15] [16] or provided only short follow-up periods. 8, 9, 16 We sought to determine whether or not smoking is associated with decline in memory and other cognitive functions in elderly persons without dementia or cognitive impairment without dementia (CIND) at baseline.
Similarities subtest 24 and the nonverbal Identities and Oddities subtest of the Mattis Dementia Rating Scale. 25 Visuospatial ability was examined using the Rosen Drawing Test 26 and a matching version of the Benton Visual Retention Test. 27 Memory was evaluated using the multiple-choice version of the Benton Visual Retention Test 27 and the seven subtests of the Selective Reminding Test: 28 total recall, long-term recall, long-term storage, continuous long-term storage, words recalled on last trial, delayed recall, and delayed recognition. This neuropsychological test battery has established norms for the same community. 29 Definition of dementia and cognitive impairment. Results from the neurologic, psychiatric, and neuropsychological examinations were reviewed in a consensus conference comprised of physicians, neurologists, neuropsychologists, and psychiatrists. Based on this review, all participants were assigned to one of three categories: normal cognitive function, CIND, or dementia. A diagnosis of CIND required: 1) memory complaint; 2) objective impairment in at least one cognitive domain based on the average of the scores on the neuropsychological measures within that domain and a 1.5 SD cutoff using normative corrections for age, years of education, ethnicity and sex; 3) essentially preserved activities of daily living; and 4) no evidence for dementia. Dementia was defined as the presence of abnormalities in several cognitive domains in neuropsychiatric testing accompanied by significant functional impairment (Clinical Dementia Rating [CDR] Ն 1).
Smoking. A structured risk-factor questionnaire, given in English or Spanish, was developed for the assessment of exposures to putative risk factors related to dementia. 30 A trigger question asked whether or not the individual ever smoked at least one cigarette per day for a period of 1 year or more. If the answer to the trigger question was no, the subject was classified as nonsmoker and no further questions were asked. Participants who answered the question affirmatively were classified as current smokers if they were still smoking or past smokers if they had quit smoking. Current and past smokers were additionally asked at what age they began smoking and how many cigarettes on average they had smoked or still smoked per day. Past smokers were also asked at what age they had stopped smoking.
APOE genotyping. APOE genotypes were determined as described by Hixson and Vernier 31 with slight modification. 32 We classified persons as homozygeous or heterozygeous for the APOE-ε4 allele or not having any ε4 allele.
Other covariates. Diabetes mellitus and hypertension were defined by self-report at baseline and at each follow-up interval or by the use of disease-specific medications. Blood pressure measurements were also considered in the definition of hypertension. Body mass index (BMI) was calculated by the formula BMI ϭ weight (kg)/height (m) 2 .
Statistical methods. A factor analysis was performed using data from the entire cohort with the 15 neuropsychological measures using a principal component analysis with varimax rotation and Kaiser normalization. 33 This analysis resulted in three factors: 1) a memory factor, in which the seven subtests of the Selective Reminding Test 28 were the main contributors; 2) an abstract/ visuospatial factor, where visuospatial 26, 27 and tests of reasoning 24 were the main contributors; and 3) a language factor, in which language measures from the Boston Naming Test, 21 Controlled Oral Word Association Test, 22 and the WAIS-R Similarities 24 were the main contributors. We calculated cognitive scores for each participant at each visit by adding the scores of the measures that contributed most to each factor (tests with correlations of Ն0.5). Each factor score was normally distributed.
Generalized estimating equations (GEEs) 34 were used to examine changes in each cognitive domain over time. The dependent variables were the factor scores, and the independent variables were current smoking, past smoking, time (included as a continuous variable), and the interaction of smoking and time. Sex, age, education, ethnic group, APOE-ε4 allele, hypertension, and heart disease were included as covariates in subsequent analyses.
The GEE analysis yielded coefficient values that represent the associations between a factor score and variables included in the model. There were three main coefficients of interest in each model: one comparing the smoking groups at baseline, one relating the change in cognitive scores with time, and an interaction term for current or past smoking and time. A significant p value for the coefficient comparing smoking groups at baseline indicates a difference between two groups at baseline. A significant p value for the coefficient of time indicates a change in a cognitive score over the total duration of follow-up. A significant p value for the interaction coefficient indicates a difference in the rate of change in a factor score depending on the smoking group; this is the main variable of interest for the interpretation of the analyses. All analyses were repeated after stratifying for median of age. Men were more often current or past smokers than women (table 2) . Blacks were less often never smokers but more often current smokers than whites and Hispanics.
Results
In the GEE analysis memory, abstract/visuospatial and language performance declined over time. Increased age at baseline was related to lower scores in all three cognitive domains at each interval, whereas higher education and white ethnicity were associated with higher scores in all domains at each interval. Current or past smoking was not associated with more rapid cognitive decline in analyses for the whole sample (p for interaction of smoking and time ϭ 0.2).
These analyses were repeated stratifying by median of age (75.6 years). Current smokers aged Ͼ75 years showed significantly lower scores in abstract/visuospatial performance at baseline than never or past smokers (table 3) and they showed a decline over the follow-up in memory (p ϭ 0.05). Thus, memory performance declined at a faster rate among current smokers aged Ͼ75 years than in subjects of similar age who never smoked or quit smoking (table 4) . These associations remained significant after adjusting for age, sex, ethnic group, education, APOE-ε4 allele and potential vascular risk factors such as hypertension and heart disease. In participants without the APOE-ε4 allele who were aged Ͼ75 years, smoking substantially increased the risk of cognitive and memory decline, whereas carriers of APOE-ε4 showed no relation between smoking and memory or abstract/visuospatial performance (table 5) .
There was no association between smoking and decline in language or abstract-visuospatial test (tables 3 and 6). Scores of both factors were normally distributed at each time interval indicating that the lack of a total current Discussion. In this study, the performance in memory, abstract-visuospatial, and language domains over time declined in individuals free of dementia or cognitive impairment at baseline, and increased age was associated with lower scores in all cognitive domains. Current smoking was associated with faster cognitive decline only in memory among subjects aged Ͼ75 years without the APOE-ε4 allele.
Past smoking was not associated with poor performance in any cognitive domain at any specific time interval, or decline in any domain over time.
The mechanisms by which smoking affects cognitive performance remain unclear. It has been proposed that smoking may increase the risk of dementia through cerebrovascular disease, 35 or that it augments cholinergic metabolism by upregulation of cholinergic nicotinic receptors in the brain. 36 Cholinergic deficits, characterized by reduced levels of acetylcholine and nicotinic receptors, are found in AD. 37 However, nicotine increases acetylcholine release, elevates the number of nicotinic receptors, and improves attention and information processing. 38 These actions may be opposed by high oxidative stress caused by smoking, which is a putative mech- anism in AD, 39, 40 through generation of free radicals and affecting inflammatory-immune systems, which activate phagocytes that generate further oxidative damage. 41 There is also evidence that smokers have a lower dietary intake of antioxidants compared with nonsmokers. 42 Studies examining the role of smoking in cognitive function reported inconsistent results. Several casecontrol studies suggested that smoking might be related to a lower risk of AD, 6 but prospective studies reported an increased risk of AD 4, 5, 7 or no association. [8] [9] [10] Our results are consistent with studies showing an increased risk of AD in current smokers. The main cognitive domain affected in AD is memory 43, 44 and it seems reasonable to postulate that if smoking is related to a higher risk of AD, it must be related to decline in memory.
We found that the association between current smoking and AD was restricted to persons older than 75 years of age. The risk of AD increases with age 43 and our finding may indicate that smoking increases the risk of memory decline in those who are more likely to develop memory decline. We also found that the association between current smoking and faster cognitive decline was confined to subjects without the APOE-ε4 allele. This is in agreement with a previous study reporting an increased risk of AD in participants without the APOE-ε4 allele. 7 The presence of the APOE-ε4 allele increases the risk of AD. 45 Older individuals with the APOE-ε4 may have an increased risk of memory decline 46 in a such a way that other risk factors may not increase the risk further. Another potential explanation for the lack of association of smoking to memory decline in APOE-ε4 carriers is that smoking may be harmful through vascular mechanisms, but also partly beneficial in APOE-ε4 carriers. This hypothesis is supported by previous findings that persons with AD who are APOE-ε4 carriers have fewer nicotinic receptor binding sites and lower activity of choline acetyltransferase than noncarriers. 47 Smoking could counterbalance the APOE-ε4-associated impairment by facilitating the release of acetylcholine or increasing the density of nicotine receptors. There are several potential alternative explanations for our findings. One is chance, particularly in the context of multiple comparisons. However, our findings were not unexpected, are consistent with our previous findings relating current smoking to a higher risk of AD, 5 and consistent with other studies as described in the previous paragraph; these facts make chance due to multiple comparisons an unlikely explanation for our findings. 48 Another potential explanation is bias. For example, only subjects with preclinical AD reported smoking, whereas subjects that would not develop AD did not. This type of reporting bias seems unlikely and we excluded cases of incipient dementia or cognitive impairment that could have influenced our results. Another potential explanation is confounding. For example, if lower education is related to current smoking, and persons with lower education are more likely to be diagnosed with AD, then it is possible that a relation between smoking and cognitive decline could be due to confounding by socioeconomic factors. We adjusted for years of education and ethnicity as markers of socioeconomic status to account for this possibility. Fi-nally, another explanation is genetic confounding. It may be that smoking propensity is associated with a gene or combination of genes (but not APOE), which in turn is associated with the risk of AD. Therefore, it is possible that smoking is related to other behaviors related to poor health or genetic factors that may increase the risk of AD, but that we could not adjust for; therefore, we cannot eliminate the possibility of lack of control for unknown confounders as a potential explanation for our findings.
This study has several strengths. We had a comprehensive and sensitive neuropsychological battery validated for use in the communities of northern Manhattan. 18 We also excluded from our analyses persons with dementia and cognitive impairment without dementia at baseline that may have biased the analyses, and had several evaluation time points that allowed prospective analyses.
The main limitation of this study is the ascertainment of smoking status. We relied on self-report by participants and did not have information on quantity or duration of smoking. Assuming random misclassification of smoking, this would have resulted in the underestimation of the association between smoking and cognitive impairment. Given that we excluded subjects with dementia and with cognitive impairment without dementia at baseline from the analyses, it seems unlikely that the report of smoking status was influenced by cognitive status.
It is important to point out that this study was conducted in an elderly multiethnic community in an urban setting with a high prevalence of risk factors for morbidity and mortality, such as diabetes and hypertension. Persons who dropped out of the study before completing at least three follow-up visits were at baseline older, less educated, and had a higher prevalence of vascular risk factors than those who remained in the study. Also, smoking is related to higher mortality from various causes, and it is possible that many smokers would have demonstrated cognitive decline had they not died prior to inclusion in this cohort. Thus, there are important biases related to the sample of this study that should be taken into account in the interpretation and generalization of these findings. 
